Evidence map›Paper›PMID 40817983›Full record

SynthesisWorld journal of urology2025

Reintervention rates after minimally invasive benign prostatic hyperplasia therapies: a systematic review including industry involvement.

Burak Akgul, Atınc Tozsin, Abdullatif Aydın, Theodoros Tokas, Javier Romero-Otero, Gernot Ortner, Christopher Netsch, Thomas Rw Herrmann, Jens Rassweiler, Kamran Ahmed and 1 more

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Burak AkgulDepartment of Urology, Trakya University School of Medicine, Edirne, Turkey.
Atınc TozsinDepartment of Urology, Trakya University School of Medicine, Edirne, Turkey.
Abdullatif AydınDepartment of Urology, King's College London Hospital NHS Foundation Trust, London, United Kingdom.
Theodoros TokasDepartment of Urology, General Hospital of Heraklion, University of Crete, Heraklion, Greece.
Javier Romero-OteroDepartment of Urology, ROC Clinic and Fundación Investigación HM Hospitales, Madrid, Spain.
Gernot Ortner, Hall in Tirol, Austria.
Christopher NetschDepartment of Urology, Asklepios Clinic Barmbek, Hamburg, Germany.
Thomas Rw HerrmannDepartment of Urology, Kantonspital Thurgau AG, Pfaffenholzstrasse, Frauenfeld, Switzerland.
Jens RassweilerDepartment of Urology and Andrology, Danube Private University, Krems, Austria.
Kamran AhmedDepartment of Urology, King's College London Hospital NHS Foundation Trust, London, United Kingdom.
Selcuk GuvenDepartment of Urology, Necmettin Erbakan University, Konya, Turkey. selcukguven@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMinimally invasive surgical therapies (MIST) for benign prostatic hyperplasia (BPH) provide effective alternatives to traditional surgery. At the same time, long-term reintervention rates and industry sponsorship influence remain critical in clinical decision-making. We systematically assessed surgical reintervention rates, medical therapy initiation following MISTs, and the impact of industry sponsorship on study outcomes.

methodsWe systematically reviewed prospective and retrospective studies in MEDLINE, EMBASE, and Cochrane Library (up to December 2024) according to PRISMA guidelines (CRD42024617974). Risk analysis evaluated conflicts of interest (COI) and sponsor influence.

resultsOf 99 studies, surgical reintervention rates were 13.6% for Prostatic Urethral Lift(PUL) (5 years), 11.1% for Water Vapor Thermal Therapy(WVTT)(5 years), 4.4%-6% for Aquablation (5 years), 21% for Prostatic Artery Embolization(PAE) (2 years), 2.5% for Optilume BPH Catheter System(OBCS) (2 years), 11.1% for Temporarily Implantable Nitinol Device (iTIND) (4 years), 13.8%-26.4% for Transurethral Needle Ablation(TUNA) (5-10 years), and 67% for Transurethral Microwave Therapy (TUMT) (5 years). Medical therapy initiation rates reached 10.7% for PUL (5 years), 11.1% for WVTT (5 years), 4.4% for Aquablation (5 years), 2.5% for OBCS (4 years), and 24.5% for TUMT (5 years). Industry sponsorship was high-risk in 65% of studies, and sponsor influence was 52%, raising objectivity concerns. Variability in follow-up durations and therapy initiation rates limits comparability.

conclusionsPAE, TUMT, and TUNA show higher reintervention rates, while OBCS (4 years) and both Aquablation and WVTT (5 years) demonstrate lower rates. Industry-sponsored studies often apply restrictive inclusion, yielding favorable results that may not fully translate to broader, real-world populations. Caution is needed when integrating these findings into clinical guidelines, particularly given potential COI.

Indexed as

Minimally Invasive Surgical ProceduresProstatic HyperplasiaReoperationConflict of InterestHumansIndustryMaleBenign prostatic hyperplasiaLower urinary tract symptomsMinimally invasive surgical proceduresReintervention

Identifiers

PMID40817983

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.